Welcome to our dedicated page for DEFENCE THERAPEUTICS A news (Ticker: DTCFF), a resource for investors and traders seeking the latest updates and insights on DEFENCE THERAPEUTICS A stock.
Defence Therapeutics Inc. (symbol: DTCFF) is a Canadian biopharmaceutical company specializing in immune-oncology therapeutics and drug delivery technologies. The company recently announced the successful development of its second-generation ARMTM anti-cancer vaccine, ARM-002TM, which has shown therapeutic effectiveness against pre-established melanoma when combined with an anti-PD-1 immune-checkpoint inhibitor. Defence's unique approach involves the use of reprogrammed mesenchymal stromal cells and AccuTOX® to induce potent antigen presentation for enhanced immune response. The ARM-002TM vaccine is highly versatile and adaptable, being tested on
Defence Therapeutics, a biopharmaceutical firm, announced the issuance and allowance of multiple patents across several Patent Families. The US Patent Office allowed application no. 18/169,440, enhancing the company's vaccine platform technology, Accum®, known for boosting antigen presentation. Recent pre-clinical studies using Defence's ARM-002™ vaccine showed significant antitumor responses, paving the way for Phase I trials.
Another patent in Australia for Defence's ADC platform was granted on February 1, 2024, further protecting Accum® and its variants, and adding to existing patents in the US, Japan, and Israel. Additionally, patents for Defence's vaccine platform technology were granted in Canada and Australia, with a Japanese patent expected soon. These patents cover methods and compositions for enhancing antigen immunogenicity.
CEO Mr. Plouffe highlighted the importance of these patents in Defence's mission to innovate and improve human health. The company is accelerating the examination of remaining applications via the Patent Prosecution Highway (PPH) program.
Defence Therapeutics Inc. announces successful completion of a pre-clinical vaccination trial using its ARM-002TM vaccine against pancreatic cancer, showing therapeutic effectiveness when combined with an immune-checkpoint inhibitor. Results reveal potent vaccine efficacy with tumor growth inhibition, positioning the company to target 'hard-to-treat' cancers like pancreatic cancer. The pancreatic cancer market is projected to exceed USD 36 billion by 2036.
FAQ
What is the current stock price of DEFENCE THERAPEUTICS A (DTCFF)?
What is the market cap of DEFENCE THERAPEUTICS A (DTCFF)?
